No Data
Viva Biotech Holdings Announces Positive Profit Turnaround for 2024
VIVA BIOTECH (01873.HK) expects to turn a profit for the year.
Gelonghui reported on March 13 that VIVA BIOTECH (01873.HK) announced that compared to a net loss of 99.8 million yuan in the previous year and a net loss attributable to shareholders of 116.1 million yuan for the 2023 fiscal year, the group expects to turn a profit by the end of the fiscal year on December 31, 2024, with net income ranging between 210 million yuan and 240 million yuan, and net income attributable to shareholders ranging between 150 million yuan and 180 million yuan. The group anticipates an adjusted net income and net income attributable to shareholders (after deducting one-time restructuring expenses and properties,
Express News | VIVA Biotech Holdings - Expects Net Profit of RMB210 Mln to RMB240 Mln for 2024
VIVA BIOTECH: POSITIVE PROFIT ALERT
GF Securities Starts Viva Biotech at Buy With HK$2.41 Price Target
[Brokerage Focus] GF SEC gives VIVA BIOTECH (01873) a "Buy" rating, indicating that its CRO Business is expected to improve profitability.
Jinwu Financial News | GF SEC research pointed out that based on rich underlying data and foundational experience, VIVA BIOTECH (01873) has established various high-quality databases in conjunction with the company's supercomputing center capabilities, achieving a closed-loop iteration of AI and experimental data, forming a one-stop AIDD platform covering areas such as small molecules, antibodies, and peptides. As of the end of the first half of 2024, the company has completed a total of 49 CADD/AIDD projects, of which long-term projects account for 35%; the cumulative number of clients purchasing CADD/AIDD reaches 40. The AIDD technology platform is expected to continuously enhance the company's efficiency and competitiveness in the future.
